Glaxo drug shown to delay ovarian cancer relapse

By Deena Beasley

CHICAGO | Sat Jun 1, 2013 7:31am EDT

CHICAGO (Reuters) – A cancer drug sold by GlaxoSmithKline was shown in a clinical trial to extend survival by several months for ovarian cancer patients whose disease had returned after initial surgery and chemotherapy.

The findings suggest that the oral drug, Votrient, could be used as a “maintenance” therapy for many ovarian cancer patients.

Votrient, designed to interfere with the growth of new blood vessels that tumors need to survive, is approved in the United States to treat people with kidney cancer or soft-tissue sarcoma, a group of rare but aggressive cancers that usually begin in the muscles, fat or other tissues.

A large-scale Phase 3 trial in women with advanced ovarian cancer found that the drug, also known as pazopanib, extended the time patients lived without their disease getting worse by an average of 5.6 months, compared with a placebo treatment.

The study was presented on Saturday at the annual meeting of the American Society of Clinical Oncology in Chicago.

An estimated 230,000 women worldwide are diagnosed with ovarian cancer each year. Most are not diagnosed before the cancer has spread, and up to 70 percent of them die within five years.

Some patients can be cured with surgery and chemotherapy, but doctors have no way to predict who they are.

“Our findings show that we finally have a drug that can maintain control over ovarian cancer growth achieved through initial treatments,” lead study author Dr Andreas du Bois, professor of gynecologic oncology at Kliniken Essen Mitte in Essen, Germany, said in a statement. “If pazopanib is approved for ovarian cancer, many patients will experience longer disease-free and chemotherapy-free periods.”

The study, which involved 940 patients who had prior surgery and at least five rounds of chemo, found that the median time to disease worsening in the pazopanib and placebo groups was 17.9 months and 12.3 months, respectively.

An interim analysis found no difference in overall survival between the two groups.

Side effects seen in the trial included hypertension, diarrhea, and nausea. Votrient was associated with the deaths of two trial patients.

The Glaxo drug carries a boxed warning, the most serious kind, about its potential link to liver damage, which can be fatal. Researchers said none of the patients in the ovarian cancer trial experienced liver failure, although some did have elevated liver enzymes which were manageable.

(Reporting By Deena Beasley; Editing by Kenneth Barry)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

Visit the Source Site

Dutch authorities to cull poultry after avian influenza outbreak

AMSTERDAM | Sat Jun 1, 2013 8:20am EDT

AMSTERDAM (Reuters) – Health authorities will cull 11,000 chickens at a farm in the Netherlands after an outbreak of a mild form of avian influenza, the Dutch Economic Affairs Ministry said on Saturday.

The chickens were believed to have the low pathogenic H7 strain, the ministry said in a statement. They would be culled as a precaution because the strain can mutate into a form that is fatal for poultry.

Authorities imposed a one-kilometer safety perimeter around the farm banning transports of poultry, eggs and other farm products. Testing would also be carried at 11 other farms in the area, it said.

In recent years several cases of the low pathogenic bird flu strain have been reported in the Netherlands.

The most devastating outbreak of H7N7 avian flu in the country was in 2003 and led to the culling of 30 million birds, about a third of the nation’s poultry flock.

Visit the Source Site